Patterns of care for women with ovarian cancer in the United States

Journal of Clinical Oncology

Volumn 15, Issue 11, 1997, Pages 3408-3415

  Muñoz, Kathryn Anne ^a   Harlan, Linda C ^a   Trimble, Edward L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; UNITED STATES;

EID: 0342981463     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.11.3408     Document Type: Article

References (48)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1996 [see comments]. CA Cancer J Clin 46:5-27, 1996
2. Yancik R, Ries LA: Cancer in older persons. Magnitude of the problem - How do we apply what we know? Cancer 74:1995-2003, 1994
3. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995 [published erratum appears in CA Cancer J Clin 45:127-128,1995]. CA Cancer J Clin 45:8-30, 1995
4. de Souza PL, Friedlander ML: Prognostic factors in ovarian cancer. Hematol Oncol Clin North Am 6:761-782, 1992
5. Schueler JA, Cornelisse CJ, Hermans J, et al: Prognostic factors in well-differentiated early-stage epithelial ovarian cancer. Cancer 71:787-795, 1993
6. Sevelda P, Vavra N, Schemper M, et al: Prognostic factors for survival in stage I epithelial ovarian carcinoma. Cancer 65:2349-2352, 1990
7. Sigurdsson K, Aim P, Gullberg B: Prognostic factors in malignant epithelial ovarian tumors. Gynecol Oncol 15:370-380, 1983
8. Dembo AJ, Davy M, Stenwig AE, et al: Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 75:263-273, 1990
9. Friedlander ML, Dembo AJ: Prognostic factors in ovarian cancer. Semin Oncol 18:205-212, 1991
10. Cannistra SA: Cancer of the ovary [published erratum appears in N Engl J Med 10:448, 1994; see comments]. N Engl J Med 329:1550-1559, 1993
11. Qazi F, McGuire WP: The treatment of epithelial ovarian cancer [see comments]. CA Cancer J Clin 45:88-101, 1995
12. Trimble CL, Trimble EL: Management of epithelial ovarian tumors of low malignant potential. Gynecol Oncol 55:S52-S61, 1994
13. Colombo N, Chiari S, Maggioni A, et al: Controversial issues in the management of early epithelial ovarian cancer: Conservative surgery and role of adjuvant therapy. Gynecol Oncol 55:S47-S51, 1994
14. Hacker NF, Van der Burg ME: Advanced ovarian cancer. Debulking and intervention surgery. Ann Oncol 4:17-22, 1993 (suppl 4)
15. NIH Consensus Conference: Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 273:491-497, 1995
16. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: Screening, treatment, and follow-up. Gynecol Oncol 55:54-14, 1994
17. Trimble EL: The NIH Consensus Conference on Ovarian Cancer: Screening, treatment, and follow-up. Gynecol Oncol 55:S1-S3, 1994
18. Thigpen JT, Blessing JA, Vance RB, et al: Chemotherapy in ovarian carcinoma: Present role and future prospects. Semin Oncol 16:58-65, 1989
19. Thigpen T, Blessing JA: Current therapy of ovarian carcinoma: An overview. Semin Oncol 12:47-52, 1985
20. Thigpen JT, Lambuth BW, Vance RB: Management of stage I and II ovarian carcinoma. Semin Oncol 18:596-602, 1991
21. Thigpen T: Systemic therapy with single agents for advanced or recurrent endometrial carcinoma. Cancer Treat Res 49:93-106, 1989
22. Williams CJ, Mead GM, Macbeth FR, et al: Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: Mature results of a randomized trial. J Cln Oncol 3:1455-1462, 1985
23. Omura GA, Bundy BN, Berek JS, et al: Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 7:457-465, 1989
24. Omura G, Blessing JA, Ehrlich CE, et al: A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group study. Cancer 57:1725-1730, 1986
25. Williams CJ, Stewart L, Parmar M, et al: Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group. Semin Oncol 19:120-128, 1992
26. Swenerton KD, Pater JL: Carboplatin in the treatment of carcinoma of the ovary: The National Cancer Institute of Canada experience. Ovarian Cancer Subcommittee. Semin Oncol 19:114-119, 1992
27. Alberts DS, Canetta R, Mason-Liddil N: Carboplatin in the first-line chemotherapy of ovarian cancer. Semin Oncol 17:54-60, 1990
28. Mangioni C, Bolis G, Pecorelli S, et al: Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin [see comments]. J Natl Cancer Inst 81:1464-1471, 1989
29. Green JB, Green S, Alberts DS, et al: Carboplatin therapy in advanced endometrial cancer. Obstet Gynecol 75:696-700, 1990
30. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
31. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with IC.-9-CM administrative databases. J Clin Epidemiol 45:613-619, 1992
32. Yancik R: Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71:517-523, 1993
33. Ries LA: Ovarian cancer. Survival and treatment differences by age. Cancer 71:524-552, 1993
34. Markman M, Lewis JL Jr, Saigo P, et al: Impact of age on survival of patients with ovarian cancer. Gynecol Oncol 49:236-239, 1993
35. Hightower RD, Nuguyen HN, Averette HE, et al: National Survey of Ovarian Carcinoma IV: Patterns of care and related survival for older patients. Cancer 73:377-383, 1994
36. Yancik R, Ries LG, Yates JW: Ovarian cancer in the elderly: An analysis of Surveillance. Epidemiology, and End Results program data. Am J Obstet Gynecol 154:639-647, 1986
37. Kennedy AW, Flagg JS, Webster KD: Gynecologic cancer in the very elderly. Gynecol Oncol 32:49-54, 1989
38. Kosary CL: FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: An analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 10:31-46, 1994
39. Balvert-Locht HR, Coebergh JW, Hop WC, et al: Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: A registry-based study. Gynecol Oncol 42:3-8, 1991
40. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 334:1-6, 1996
41. Young RC, Decker DG, Wharton JT, et al: Staging laparotomy in early ovarian cancer. JAMA 250:3072-3076, 1983
42. Finn-CB, Luesley-DM, Buxton-EJ, et al: Is stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review. Br J Obstet Gynaecol 99:54-58, 1992
43. Liberati A, Mangioni C, Bratina L, et al: Process and outcome of care for patients with ovarian cancer. Br Med J 291:1007-1012, 1985
44. Ayanian JZ, Kohler BA, Abe T, et al: The relation between health insurance coverage and clinical outcomes among women with breast cancer [see comments]. N Engl J Med 329:326-331, 1993
45. McGowan L: Patterns of care in carcinoma of the ovary. Cancer 71:628-633, 1993
46. Nuguyen HN, Averette HE, Hoskins W, et al: National Survey of Ovarian Carcinoma Part V: The impact of physician's specialty on patients' survival. Cancer 72:3663-3670, 1993
47. Junor EJ, Hole DJ, Gillis CR: Management of ovarian cancer: Referral to a multidisciplinary team matters. Br J Cancer 70:363-370, 1994
48. Greenberg ER, Chute CG, Stukel T, et al: Social and economic factors in the choice of lung cancer treatment. A population-based study in two rural states. N Engl J Med 318:612-617, 1988